Elekta Introduces Advanced Cancer Treatment to Kingdom of Bhutan
THIMPHU, Bhutan, July 24, 2017 -- (Healthcare Sales &Marketing Network) -- Elekta (EKTA-B.ST) announced today that it has been chosen to deliver the first ever radiation therapy system to the Kingdom of Bhutan. The National Referral Hospital, the largest... Devices, Oncology Elekta, Elekta Compact, linear accelerator, radiotherapy
Each year, MD+DI’s editors gather to choose which company should be named the Medtech Company of the Year, and it’s always a heated debate. This year, we named nine finalists, but the decision to crown Abbott as our 2017 Medtech Company of the Year was unanimous. Our readers, however, had a different opinion. While MD+DI’s editors chose Abbott for its ability to rise above challenges, Bigfoot Biomedical was the favorite among our readership. The Milpitas, CA-based firm is amalgamating other companies’ hardware plus its own software and algorithms to craft an artificial pancreas for patients with dia...
Condition: Pancreatic Cancer Interventions: Radiation: Radiation; Drug: SHR-1210 Sponsors: Shixiu Wu; Jiangsu HengRui Medicine Co., Ltd. Recruiting
Accurate grading and staging are essential to ensure that men with prostate cancer are risk stratified correctly and thereby treated appropriately. In particular, high grade cancers are aggressively treated with surgery, high dose radiation therapy and years of androgen deprivation.1 These treatments are fortunately associated with higher cure rates but they may unfortunately negatively impact quality of life.
We report the case of a 49-year-old patient who developed brain, sternal, and spine metastases almost simultaneously after the radical resection of a yp-T4N0M0 pulmonary pleomorphic carcinoma of the right upper lobe following induction chemotherapy. The left occipital brain metastasis was surgically removed and followed by radiation therapy. The sternal and vertebral metastases were treated with radiation therapy. Concurrently, the immune checkpoint inhibitor nivolumab was administered. After 12 cycles of nivolumab, the two bone metastases were well-controlled. However, the brain metastasis recurred and was surgically remo...
Radiation therapy with androgen deprivation therapy (ADT) has historically been one of the mainstays of treatment for intermediate- and high-risk prostate cancer. The benefit of ADT likely derives from both enhancing local control and inhibiting micrometastatic disease. While level 1 evidence has demonstrated the benefits of 4 –6 months of ADT for all men with intermediate-risk disease, further stratification of intermediate-risk prostate cancer into favorable and unfavorable subgroups indicates that ADT may not be necessary for favorable intermediate-risk disease but likely still provides a survival advantage for un...
Conclusion: Targeted molecular therapy and immunotherapy in LMD may provide favorable treatment options. Current literature is lacking in safety, efficacy, and overall response rates from the use of targeted therapy. Research is needed to draw significant conclusions about the most appropriate therapy for patients with LMD. PMID: 29230121 [PubMed]
Conclusions Local irradiation with a fractional dose of 3.0–5.5Gy(RBE) and a cumulative dose of 28.0–28.8Gy(RBE) for protons significantly reduces the early and late rectitis severity, but does not reduce the risk of lower urinary tract injuries. Fractionation regimens do not significantly differ in toxicity levels.
Conclusions The findings of this study indicate that IMRT is well tolerated and is associated with both good long-term tumor control and excellent outcomes in patients with localized prostate cancer.
Radiation therapy is one of the primary treatments in fighting breast cancer, one of the most common cancers in the US. One of the dose limiting factors of this therapy is radiation induced heart damage that results from mediastinal radiation. Recently statins, a medication typically used to lower cholesterol levels, have been suggested as a prophylactic treatment to potentially mitigate this process. Similarly, we hypothesized whether colchicine, an anti-inflammatory medication that is presently used in the treatment of gout and pericarditis, might be used to prevent coronary artery disease induced by radiation therapy.
Publication date: Available online 8 December 2017 Source:Practical Radiation Oncology Author(s): Martha M. Matuszak, Peter Paximadis, Mark Yudelev, Margaret Grubb, Melissa L. Wilson, Correen Fraser, Praveen Dalmia, Ahmad Alkhatib, David E. Sieffert, Joe R. Haywood, Daniel Tatro, Jan Parker, Omer Ettaher, Inga Grills, Larry Kestin, Eleanor M. Walker, Courtney Friedle, Harold Kim, Jeffrey D. Radawski, Thomas Boike, Jean M. Moran, Lori J. Pierce, James A. Hayman